PAX3 and rhabdomyosarcoma: Milewski et al. found that FOXF1 is downstream of PAX3-FOXO1 in rhabdomyosarcoma, promoting tumor development, and FOXF1 may be a potential therapeutic target for rhabdomyosarcoma [19].